Jan 13 2006 | 8:30pm ET
• Private equity firm Aisling Capital has closed it its life sciences fund, Aisling Capital II, With $550 million in commitments. The New York-headquartered Aisling, which has $1 billion in assets under management, was spun-out of Perseus-Soros Management. Aisling will invest primarily in life science companies that are developing biopharmaceutical products and creating businesses based on advanced life science technologies. Dennis Purcell, senior managing director of Aisling, said in a release, "we continue to believe that opportunities exist in all areas of the life sciences industry and will implement a strategy similar to the first fund."
Jul 8 2014 | 10:48am ET
The surge in derivatives regulation is among the most complex challenges facing the financial services industry today. Northern Trust’s Joshua Satten recently spoke with FINalternatives to share insights into the challenges presented by new regulation and explore how the industry is responding. Read more…